Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYH2061 in Healthy Subjects
NCT07241910Phase 1Recruiting
- Sponsor
- CSPC Zhongnuo Pharmaceutical
- Start
- Dec 2025
- Primary completion
- Nov 2026
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing SYH2061 group with Placebo group (2 arms). Primary endpoint: Number of Subjects with Adverse Events. Started Dec 2025; status: recruiting.
02
Drugs
SYH2061
Beyond the preview
Go deeper on NCT07241910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07241910.